Forecasting Medicaid Expenditures for Antipsychotic Medications.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Psychiatric Services

• Publication date

  2015-03-31

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1176/appi.ps.201400042PMID 25828875
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.

  2014cited by this paper
• The diminished pipeline for medications to treat mental health and substance use disorders.

  2014cited by this paper
• Off-label use of antipsychotic medications in Medicaid.

  2012cited by this paper
• Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.

  2011cited by this paper
• Unintended Impacts of a Medicaid Prior Authorization Policy on Access to Medications for Bipolar Illness

  2010cited by this paper
• Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder.

  2009cited by this paper
• Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements.

  2008cited by this paper
• Medicaid's prior authorization program and access to atypical antipsychotic medications.

  2007cited by this paper
• Medicaid policies to contain psychiatric drug costs.

  2005cited by this paper
• Mental health policy and psychotropic drugs.

  2005cited by this paper
• Benefits and risks of increasing restrictions on access to costly drugs in Medicaid.

  2004cited by this paper
• Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill.

  2003cited by this paper
• A Simple Model of Pharmaceutical Price Dynamics*

  2003cited by this paper

• Predicting the Pharmaceutical Needs of Hospitals

  2024cites this paper
• Descriptive Trends in Medicaid Antipsychotic Prescription Claims and Expenditures, 2016 – 2021

  2024cites this paper
• Predicting the pharmaceutical needs of hospitals using machine learning algorithms

  2024cites this paper
• Forecasting drug utilization and expenditure: ten years of experience in Stockholm

  2020cites this paper
• A Bayesian hierarchical model for characterizing the diffusion of new antipsychotic drugs

  2020cites this paper
• A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US

  2018cites this paper
• Cost-Effectiveness of Comprehensive, Integrated Care for First Episode Psychosis in the NIMH RAISE Early Treatment Program.

  2016cites this paper
• The introduction of generic risperidone in Medicare Part D.

  2016cites this paper
• Brexpiprazole: A New Antipsychotic Following in the Footsteps of Aripiprazole.

  2015cites this paper